N-Acetylprocainamide kinetics and clinical response during repeated dosing

Area of Science:

• Pharmacokinetics
• Clinical Pharmacology
• Cardiology

Background:

• Chronic ventricular arrhythmias often require effective antiarrhythmic drug therapy.
• N-acetylprocainamide (NAPA) is an antiarrhythmic agent with variable clinical outcomes.
• Understanding NAPA pharmacokinetics is crucial for optimizing its use in difficult-to-treat patients.

Purpose of the Study:

• To evaluate the pharmacokinetics and clinical response to N-acetylprocainamide (NAPA) in patients with chronic ventricular arrhythmias.
• To assess the feasibility of developing patient-specific kinetic models for NAPA therapy.
• To determine NAPA's efficacy and safety in patients refractory to standard antiarrhythmic drugs.

Main Methods:

• Kinetics and clinical responses of N-acetylprocainamide (NAPA) were studied in 10 patients with chronic ventricular arrhythmias.
• NAPA concentrations were measured (n=149) during repeated dosing for kinetic data analysis.
• Clinical response was evaluated using serial 24-hour ambulatory ECGs; adverse effects were documented.

Main Results:

• An established kinetic model accurately predicted NAPA concentrations (r=0.94).
• Patient-specific kinetic models were feasible with limited serum concentrations.
• NAPA showed limited clinical effectiveness, with adverse effects in all patients, often necessitating dose reduction or discontinuation.

Conclusions:

• N-acetylprocainamide (NAPA) was not clinically effective in this cohort of patients with resistant arrhythmias.
• Adverse effects frequently limited NAPA's evaluation and use.
• The study confirmed the feasibility of patient-specific kinetic modeling for NAPA, with potential applications for other antiarrhythmic drugs.